Navigation Links
Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
Date:6/5/2008

-Results Will be Presented at the American Society for Mass Spectrometry

56th ASMS Conference in Denver, June 2-5, 2008-

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced that it has developed a novel analytical 2-dimensional liquid chromatography mass spectrometry-based (LC/LC-MS/MS) multiplexing platform that allows for the rapid, specific, sensitive automated quantification of the active pharmaceutical compounds of MF101, the company's most advanced drug candidate. The novel quantification has been initially developed for, MF101, which is botanically derived, and has shown positive Phase 2 results for the treatment of hot flashes associated with menopause. The assay was validated in multiple matrices ranging from MF101 extracts for production quality control to plasma in pharmacokinetic and safety trials.

"The development of botanical drugs is far more challenging than a single molecule drug, since these are complex mixtures containing a number of bioactive compounds," said the lead author, Dr. Yan Ling Zhang, Bionovo's Director, Analytical Chemistry. "Our assay is capable of sensitively and specifically quantifying all active MF101 compounds in one short analytical run, and allows us to prove the exquisite precision and consistency of our manufacturing process. This is a tremendous advantage over conventional assays that usually only measure single compounds."

"The availability of this robust high-throughput assay is a key to the fast and successful development of MF101," said Dr. Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "Having the tool to quantify multiple actives solves important questions for manufacturing controls, dose assessment and safety measures. This analytical platform technology is critical to move MF101 quickly through the regulatory process."

About MF101

MF101 is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to those products currently on the market, which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with estrogen receptor alpha (ER-a) activation and that estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile to hormone therapy. The drug candidate has been evaluated by an independent Data and Safety Monitoring Board and has passed through a standard two-round examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer

-- markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... AR (PRWEB) , ... July 20, 2017 , ... ... Rogers is joining the company’s board of directors. This addition continues to strengthen ... board," said Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical ... biotherapeutics development, announces the launch of a new NTA biosensor chip for use ... to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , ...
(Date:7/18/2017)... ... 18, 2017 , ... Allotrope Foundation won the 2017 in ... the Allotrope Framework for commercial use. , The Bio-IT World Best Practices Awards ... the critical role of information technology in modern biomedical research, but also to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... instruments announced the launch of its new line of Heavy-Duty Orbital Shakers today. ... (both analog and digital) for laboratory applications. These shakers are ideal for ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):